Integer Holdings Corporation (NYSE:ITGR) Receives Consensus Rating of “Hold” from Brokerages

Shares of Integer Holdings Corporation (NYSE:ITGR) have earned a consensus rating of “Hold” from the eleven brokerages that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, six have given a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $98.3750.

ITGR has been the topic of several recent analyst reports. KeyCorp cut their target price on Integer from $145.00 to $133.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 21st. Citigroup increased their price objective on Integer from $69.00 to $75.00 and gave the company a “neutral” rating in a research report on Thursday, December 11th. Argus downgraded Integer from a “buy” rating to a “hold” rating in a report on Friday, October 24th. Bank of America cut shares of Integer from a “buy” rating to a “neutral” rating and set a $87.00 target price on the stock. in a research note on Friday, October 24th. Finally, Wall Street Zen downgraded shares of Integer from a “buy” rating to a “hold” rating in a report on Sunday, January 25th.

Key Stories Impacting Integer

Here are the key news stories impacting Integer this week:

• Negative Sentiment: Multiple firms announce a securities-fraud class action against Integer covering investors who bought shares between July 25, 2024 and October 22, 2025; plaintiffs allege misleading statements and seek lead plaintiff appointments. Integer Accused of Misleading Investors — GlobeNewswire
• Negative Sentiment: Numerous plaintiff firms (Rosen, Levi & Korsinsky, Bernstein Liebhard, Pomerantz, et al.) are soliciting lead plaintiff candidates and reminding investors of a February 9, 2026 deadline to file — increasing the likelihood of consolidated litigation and legal costs. Rosen Law Firm Deadline Notice — Newsfile
• Negative Sentiment: Lawyer notices link the litigation to a prior ~32% share plunge that triggered investor losses; that drop is the proximate cause for the suits and is cited repeatedly in firm announcements. Loss Notice: Plummeted 32% — Newsfile

Integer Stock Up 0.5%

Shares of NYSE:ITGR opened at $86.87 on Friday. The company has a current ratio of 3.71, a quick ratio of 2.45 and a debt-to-equity ratio of 0.70. The stock has a fifty day simple moving average of $78.46 and a two-hundred day simple moving average of $90.90. Integer has a 12-month low of $62.00 and a 12-month high of $144.76. The stock has a market capitalization of $3.04 billion, a price-to-earnings ratio of 36.35, a PEG ratio of 0.79 and a beta of 0.78.

Integer declared that its Board of Directors has authorized a share buyback plan on Tuesday, November 4th that authorizes the company to buyback $200.00 million in outstanding shares. This buyback authorization authorizes the medical equipment provider to buy up to 8.3% of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s leadership believes its shares are undervalued.

Insiders Place Their Bets

In related news, EVP Diron Smith bought 1,116 shares of the business’s stock in a transaction on Friday, November 7th. The stock was acquired at an average price of $67.19 per share, with a total value of $74,984.04. Following the transaction, the executive vice president owned 7,698 shares in the company, valued at approximately $517,228.62. This trade represents a 16.96% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Tommy P. Thomas sold 884 shares of the stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $70.15, for a total value of $62,012.60. Following the transaction, the vice president directly owned 3,596 shares in the company, valued at $252,259.40. The trade was a 19.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 2.16% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Integer

A number of large investors have recently made changes to their positions in ITGR. Jennison Associates LLC bought a new position in shares of Integer in the 4th quarter worth approximately $1,036,000. State of New Jersey Common Pension Fund D grew its position in Integer by 59.9% during the fourth quarter. State of New Jersey Common Pension Fund D now owns 31,836 shares of the medical equipment provider’s stock valued at $2,497,000 after buying an additional 11,925 shares during the period. Inscription Capital LLC purchased a new stake in Integer during the fourth quarter valued at approximately $543,000. Vanguard Group Inc. raised its position in Integer by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 3,886,150 shares of the medical equipment provider’s stock worth $304,791,000 after acquiring an additional 14,465 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH boosted its stake in shares of Integer by 46.2% during the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 31,872 shares of the medical equipment provider’s stock worth $2,500,000 after acquiring an additional 10,079 shares during the last quarter. 99.29% of the stock is currently owned by institutional investors.

About Integer

Integer Holdings Corporation (NYSE: ITGR) is a global provider of outsourced medical device design, development and manufacturing solutions. The company partners with leading medical technology firms to deliver complex components, subsystems and finished devices across a range of therapeutic areas. Its services encompass concept and product design, precision machining, microelectronic assembly, terminal sterilization and regulatory support, enabling customers to accelerate time to market and optimize product performance.

Integer’s product portfolio is organized into two core segments: Advanced Delivery and MedTech.